{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:56:37Z","timestamp":1772297797170,"version":"3.50.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s11926-018-0709-5","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T06:37:29Z","timestamp":1519713449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature"],"prefix":"10.1007","volume":"20","author":[{"given":"Sneha M.","family":"Sundaram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"issue":"25 Suppl","key":"709_CR1","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","volume":"62","author":"G Simonneau","year":"2013","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34\u201341. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2013.10.029\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"709_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940\u20134. \n                      https:\/\/doi.org\/10.1136\/ard.2006.066068\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"709_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/art.40027","volume":"69","author":"Y Hao","year":"2017","unstructured":"Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol. 2017;69(5):1067\u201377. \n                      https:\/\/doi.org\/10.1002\/art\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"43","key":"709_CR4","doi-asserted-by":"publisher","first-page":"e1728","DOI":"10.1097\/MD.0000000000001728","volume":"94","author":"CP Simeon-Aznar","year":"2015","unstructured":"Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, et al. Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and causes of death. Medicine (Baltimore). 2015;94(43):e1728. \n                      https:\/\/doi.org\/10.1097\/MD.0000000000001728\n                      \n                    .","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"709_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.chest.2017.02.010","volume":"152","author":"S Ramjug","year":"2017","unstructured":"Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, et al. Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a comparison of demographic, hemodynamic, and MRI characteristics and outcomes. Chest. 2017;152(1):92\u2013102. \n                      https:\/\/doi.org\/10.1016\/j.chest.2017.02.010\n                      \n                    .","journal-title":"Chest"},{"issue":"6","key":"709_CR6","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1378\/chest.10-0260","volume":"138","author":"L Chung","year":"2010","unstructured":"Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383\u201394. \n                      https:\/\/doi.org\/10.1378\/chest.10-0260\n                      \n                    .","journal-title":"Chest"},{"issue":"6","key":"709_CR7","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1378\/chest.13-3014","volume":"146","author":"L Chung","year":"2014","unstructured":"Chung L, Farber HW, Benza R, Miller DP, Parsons L, Hassoun PM, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146(6):1494\u2013504. \n                      https:\/\/doi.org\/10.1378\/chest.13-3014\n                      \n                    .","journal-title":"Chest"},{"issue":"2","key":"709_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","volume":"179","author":"R Condliffe","year":"2009","unstructured":"Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151\u20137. \n                      https:\/\/doi.org\/10.1164\/rccm.200806-953OC\n                      \n                    .","journal-title":"Am J Respir Crit Care Med"},{"key":"709_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ijcard.2017.01.097","volume":"236","author":"J Zhao","year":"2017","unstructured":"Zhao J, Wang Q, Liu Y, Tian Z, Guo X, Wang H, et al. Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China. Int J Cardiol. 2017;236:432\u20137. \n                      https:\/\/doi.org\/10.1016\/j.ijcard.2017.01.097\n                      \n                    .","journal-title":"Int J Cardiol"},{"issue":"12","key":"709_CR10","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1002\/art.21433","volume":"52","author":"E Hachulla","year":"2005","unstructured":"Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792\u2013800. \n                      https:\/\/doi.org\/10.1002\/art.21433\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"11","key":"709_CR11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","volume":"62","author":"D Mukerjee","year":"2003","unstructured":"Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62(11):1088\u201393. \n                      https:\/\/doi.org\/10.1136\/ard.62.11.1088\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"709_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12890-016-0296-z","volume":"16","author":"K Morrisroe","year":"2016","unstructured":"\u2022 Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M, et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. BMC Pulm Med. 2016;16(1):134. \n                      https:\/\/doi.org\/10.1186\/s12890-016-0296-z\n                      \n                    . This paper describes the incidence and prevalence of PAH in a large Australian cohort of SSc patients (1579 patients) and also describes clinical and serologic risk factors","journal-title":"BMC Pulm Med"},{"issue":"11","key":"709_CR13","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3899\/jrheum.100245","volume":"37","author":"J Avouac","year":"2010","unstructured":"Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290\u20138. \n                      https:\/\/doi.org\/10.3899\/jrheum.100245\n                      \n                    .","journal-title":"J Rheumatol"},{"issue":"6","key":"709_CR14","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/art.24525","volume":"60","author":"E Hachulla","year":"2009","unstructured":"Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60(6):1831\u20139. \n                      https:\/\/doi.org\/10.1002\/art.24525\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"709_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.semarthrit.2014.03.002","volume":"44","author":"VM Hsu","year":"2014","unstructured":"Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS) cohort study. Semin Arthritis Rheum. 2014;44(1):55\u201362. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2014.03.002\n                      \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"709_CR16","doi-asserted-by":"publisher","first-page":"1602275","DOI":"10.1183\/13993003.02275-2016","volume":"49","author":"E Vandecasteele","year":"2017","unstructured":"Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E, et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J. 2017;49(5):1602275. \n                      https:\/\/doi.org\/10.1183\/13993003.02275-2016\n                      \n                    .","journal-title":"Eur Respir J"},{"issue":"1","key":"709_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13075-017-1250-z","volume":"19","author":"K Morrisroe","year":"2017","unstructured":"Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S, et al. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Res Ther. 2017;19(1):42. \n                      https:\/\/doi.org\/10.1186\/s13075-017-1250-z\n                      \n                    .","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"709_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-016-0933-1","volume":"18","author":"CR Pasarikovski","year":"2016","unstructured":"Pasarikovski CR, Granton JT, Roos AM, Sadeghi S, Kron AT, Thenganatt J, et al. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2016;18(1):30. \n                      https:\/\/doi.org\/10.1186\/s13075-016-0933-1\n                      \n                    .","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"709_CR19","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1378\/chest.124.6.2098","volume":"124","author":"L Schachna","year":"2003","unstructured":"Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest. 2003;124(6):2098\u2013104. \n                      https:\/\/doi.org\/10.1378\/chest.124.6.2098\n                      \n                    .","journal-title":"Chest"},{"issue":"1","key":"709_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1749-6632.2002.tb04221.x","volume":"966","author":"R Scorza","year":"2002","unstructured":"Scorza R, Caronni M, Bazzi S, Nador F, Beretta L, Antonioli R, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci. 2002;966(1):238\u201346. \n                      https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04221.x\n                      \n                    .","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"709_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1445-5994.2004.00646.x","volume":"35","author":"SR Cox","year":"2005","unstructured":"Cox SR, Walker JG, Coleman M, Rischmueller M, Proudman S, Smith MD, et al. Isolated pulmonary hypertension in scleroderma. Internal Med J. 2005;35(1):28\u201333. \n                      https:\/\/doi.org\/10.1111\/j.1445-5994.2004.00646.x\n                      \n                    .","journal-title":"Internal Med J"},{"issue":"5","key":"709_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1378\/chest.08-3042","volume":"136","author":"E Hachulla","year":"2009","unstructured":"Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136(5):1211\u20139. \n                      https:\/\/doi.org\/10.1378\/chest.08-3042\n                      \n                    .","journal-title":"Chest"},{"issue":"1","key":"709_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3899\/jrheum.090697","volume":"37","author":"AA Shah","year":"2010","unstructured":"Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98\u2013104. \n                      https:\/\/doi.org\/10.3899\/jrheum.090697\n                      \n                    .","journal-title":"J Rheumatol"},{"issue":"7","key":"709_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/acr.22766","volume":"68","author":"C Hurabielle","year":"2016","unstructured":"Hurabielle C, Avouac J, Lepri G, de Risi T, Kahan A, Allanore Y. Skin telangiectasia and the identification of a subset of systemic sclerosis patients with severe vascular disease. Arthritis Care Res (Hoboken). 2016;68(7):1021\u20137. \n                      https:\/\/doi.org\/10.1002\/acr.22766\n                      \n                    .","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"709_CR25","first-page":"114","volume":"106","author":"PE Carreira","year":"2017","unstructured":"Carreira PE, Carmona L, Joven BE, Loza E, Andreu JL, Riemekasten G, et al. Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clin Exp Rheumatol. 2017;106(4):114\u201321.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"709_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/art.10775","volume":"48","author":"V Steen","year":"2003","unstructured":"Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516\u201322. \n                      https:\/\/doi.org\/10.1002\/art.10775\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"7","key":"709_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/art.1780350709","volume":"35","author":"VD Steen","year":"1992","unstructured":"Steen VD, Graham G, Conte C, Owens G, Medsger TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992;35(7):765\u201370. \n                      https:\/\/doi.org\/10.1002\/art.1780350709\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"709_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.23187","volume":"58","author":"Y Allanore","year":"2008","unstructured":"Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58(1):284\u201391. \n                      https:\/\/doi.org\/10.1002\/art.23187\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"709_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1378\/chest.07-2324","volume":"134","author":"V Steen","year":"2008","unstructured":"Steen V, Chou M, Shanmugam V, Mathias M, Kuru T, Morrissey R. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008;134(1):146\u201351. \n                      https:\/\/doi.org\/10.1378\/chest.07-2324\n                      \n                    .","journal-title":"Chest"},{"issue":"7","key":"709_CR30","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/annrheumdis-2012-201861","volume":"72","author":"AA Shah","year":"2013","unstructured":"Shah AA, Chung SE, Wigley FM, Wise RA, Hummers LK. Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. Ann Rheum Dis. 2013;72(7):1136\u201340. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2012-201861\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"709_CR31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13075-014-0493-1","volume":"16","author":"SH Visovatti","year":"2014","unstructured":"Visovatti SH, Distler O, Coghlan JG, Denton CP, Grunig E, Bonderman D, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Res Ther. 2014;16(6):493. \n                      https:\/\/doi.org\/10.1186\/s13075-014-0493-1\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"709_CR32","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/annrheumdis-2011-200546","volume":"71","author":"S Bae","year":"2012","unstructured":"Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis. 2012;71(8):1335\u201342. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2011-200546\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"709_CR33","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.37838","volume":"65","author":"CJ Valerio","year":"2013","unstructured":"Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 2013;65(4):1074\u201384. \n                      https:\/\/doi.org\/10.1002\/art.37838\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"3","key":"709_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.semarthrit.2015.06.011","volume":"45","author":"M Hinchcliff","year":"2015","unstructured":"Hinchcliff M, Khanna S, Hsu VM, Lee J, Almagor O, Chang RW, et al. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS) registry. Semin Arthritis Rheum. 2015;45(3):309\u201314. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.011\n                      \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"709_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35\u201342. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2005.03.005\n                      \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"709_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/03009740801978871","volume":"37","author":"C Kampolis","year":"2008","unstructured":"Kampolis C, Plastiras S, Vlachoyiannopoulos P, Moyssakis I, Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol. 2008;37(4):278\u201383. \n                      https:\/\/doi.org\/10.1080\/03009740801978871\n                      \n                    .","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"709_CR37","first-page":"2230","volume":"34","author":"VD Steen","year":"2007","unstructured":"Steen VD, Lucas M, Fertig N, Medsger TA. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol. 2007;34(11):2230\u20135.","journal-title":"J Rheumatol"},{"issue":"1","key":"709_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","volume":"15","author":"SW Graf","year":"2012","unstructured":"Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012;15(1):102\u20139. \n                      https:\/\/doi.org\/10.1111\/j.1756-185X.2011.01688.x\n                      \n                    .","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"709_CR39","first-page":"199","volume":"23","author":"N Assous","year":"2005","unstructured":"Assous N, Allanore Y, Batteaux F, Meune C, Toulon P, Weill B, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol. 2005;23(2):199\u2013204.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"709_CR40","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11926-012-0302-2","volume":"15","author":"A Yaqub","year":"2013","unstructured":"Yaqub A, Chung L. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep. 2013;15(1):302. \n                      https:\/\/doi.org\/10.1007\/s11926-012-0302-2\n                      \n                    .","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"709_CR41","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1183\/09031936.00181410","volume":"39","author":"H Dib","year":"2012","unstructured":"Dib H, Tamby MC, Bussone G, Regent A, Berezne A, Lafine C, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2012;39(6):1405\u201314. \n                      https:\/\/doi.org\/10.1183\/09031936.00181410\n                      \n                    .","journal-title":"Eur Respir J"},{"issue":"7","key":"709_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3109\/08916934.2013.812080","volume":"46","author":"SJ Arends","year":"2013","unstructured":"Arends SJ, Damoiseaux JG, Duijvestijn AM, Debrus-Palmans L, Boomars KA, Brunner-La Rocca HP, et al. Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension. Autoimmunity. 2013;46(7):463\u201370. \n                      https:\/\/doi.org\/10.3109\/08916934.2013.812080\n                      \n                    .","journal-title":"Autoimmunity"},{"issue":"3","key":"709_CR43","first-page":"450","volume":"72","author":"J Rosenbaum","year":"1988","unstructured":"Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byrons MA, et al. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol. 1988;72(3):450\u20136.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"709_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0394632015572750","volume":"28","author":"C Corallo","year":"2015","unstructured":"Corallo C, Franci B, Lucani B, Montella A, Chirico C, Gonnelli S, et al. From microvasculature to fibroblasts: contribution of anti-endothelial cell antibodies in systemic sclerosis. Int J Immunopathol Pharmacol. 2015;28(1):93\u2013103. \n                      https:\/\/doi.org\/10.1177\/0394632015572750\n                      \n                    .","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"709_CR45","first-page":"462","volume":"25","author":"VS Negi","year":"1998","unstructured":"Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25(3):462\u20136.","journal-title":"J Rheumatol"},{"issue":"7","key":"709_CR46","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","volume":"190","author":"MO Becker","year":"2014","unstructured":"Becker MO, Kill A, Kutsche M, Guenther J, Rose A, Tabeling C, et al. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. Am J Respir Crit Care Med. 2014;190(7):808\u201317. \n                      https:\/\/doi.org\/10.1164\/rccm.201403-0442OC\n                      \n                    .","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"709_CR47","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493\u2013537. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehp297\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"4","key":"709_CR48","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Galie","year":"2015","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang IM, Torbicki A, et al. The 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J. 2015;46(4):879\u201382. \n                      https:\/\/doi.org\/10.1183\/13993003.01177-2015\n                      \n                    .","journal-title":"Eur Respir J"},{"issue":"3","key":"709_CR49","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/ar3876","volume":"14","author":"V Thakkar","year":"2012","unstructured":"Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther. 2012;14(3):R143. \n                      https:\/\/doi.org\/10.1186\/ar3876\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"709_CR50","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340\u20139. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2013-203301\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"709_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-017-1327-8","volume":"19","author":"A Guillen-Del Castillo","year":"2017","unstructured":"Guillen-Del Castillo A, Callejas-Moraga EL, Garcia G, Rodriguez-Palomares JF, Roman A, Berastegui C, et al. High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Res Ther. 2017;19(1):135. \n                      https:\/\/doi.org\/10.1186\/s13075-017-1327-8\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"709_CR52","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/rheumatology\/kev327","volume":"55","author":"T Soukup","year":"2016","unstructured":"Soukup T, Pudil R, Kubinova K, Hromadkova L, Dusek J, Tosovsky M, et al. Application of the DETECT algorithm for detection of risk of pulmonary arterial hypertension in systemic sclerosis: data from a Czech tertiary centre. Rheumatology (Oxford). 2016;55(1):109\u201314. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kev327\n                      \n                    .","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"709_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","volume":"17","author":"Y Hao","year":"2015","unstructured":"\u2022 Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther. 2015;17(1):7. \n                      https:\/\/doi.org\/10.1186\/s13075-015-0517-5\n                      \n                    . This paper compares three screening algorithms in 73 SSc patients, showing that the DETECT and ASIG algorithms performed with the best sensitivity and negative predictive value.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"709_CR54","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1002\/art.38172","volume":"65","author":"D Khanna","year":"2013","unstructured":"Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, et al. Recommendations for screening and detection of connective tissue disease\u2013associated pulmonary arterial hypertension. Arthritis Rheum. 2013;65(12):3194\u2013201. \n                      https:\/\/doi.org\/10.1002\/art.38172\/abstract\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"709_CR55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-015-0673-7","volume":"17","author":"C Nagel","year":"2015","unstructured":"Nagel C, Henn P, Ehlken N, D\u2019Andrea A, Blank N, Bossone E, et al. Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Res Ther. 2015;17(1):165. \n                      https:\/\/doi.org\/10.1186\/s13075-015-0673-7\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"709_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-016-1051-9","volume":"18","author":"R Baptista","year":"2016","unstructured":"Baptista R, Serra S, Martins R, Teixeira R, Castro G, Salvador MJ, et al. Exercise echocardiography for the assessment of pulmonary hypertension in systemic sclerosis: a systematic review. Arthritis Res Ther. 2016;18(1):153. \n                      https:\/\/doi.org\/10.1186\/s13075-016-1051-9\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"709_CR57","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/heartjnl-2016-309981","volume":"103","author":"D Dumitrescu","year":"2017","unstructured":"Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart. 2017;103(10):774\u201382. \n                      https:\/\/doi.org\/10.1136\/heartjnl-2016-309981\n                      \n                    .","journal-title":"Heart"},{"issue":"1","key":"709_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semarthrit.2017.03.020","volume":"47","author":"SI Mavrogeni","year":"2017","unstructured":"Mavrogeni SI, Schwitter J, Gargani L, Pepe A, Monti L, Allanore Y, et al. Cardiovascular magnetic resonance in systemic sclerosis: \u201cpearls and pitfalls\u201d. Semin Arthritis Rheum. 2017;47(1):79\u201385. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.020\n                      \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"709_CR59","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/rheumatology\/kep187","volume":"48","author":"D Hagger","year":"2009","unstructured":"Hagger D, Condliffe R, Woodhouse N, Elliot CA, Armstrong IJ, Davies C, et al. Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford). 2009;48(9):1137\u201342. \n                      https:\/\/doi.org\/10.1093\/rheumatology\/kep187\n                      \n                    .","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"709_CR60","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/acr.22121","volume":"66","author":"L Chung","year":"2014","unstructured":"Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014;66(3):489\u201395. \n                      https:\/\/doi.org\/10.1002\/acr.22121\n                      \n                    .","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"709_CR61","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1183\/13993003.00990-2016","volume":"48","author":"A Stamm","year":"2016","unstructured":"Stamm A, Saxer S, Lichtblau M, Hasler ED, Jordan S, Huber LC, et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur Respir J. 2016;48(6):1658\u201367. \n                      https:\/\/doi.org\/10.1183\/13993003.00990-2016\n                      \n                    .","journal-title":"Eur Respir J"},{"issue":"9","key":"709_CR62","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/art.38029","volume":"65","author":"G Lefevre","year":"2013","unstructured":"Lefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65(9):2412\u201323. \n                      https:\/\/doi.org\/10.1002\/art.38029\n                      \n                    .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"709_CR63","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13075-017-1341-x","volume":"19","author":"K Morrisroe","year":"2017","unstructured":"Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, et al. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther. 2017;19(1):122. \n                      https:\/\/doi.org\/10.1186\/s13075-017-1341-x\n                      \n                    .","journal-title":"Arthritis Res Ther."},{"issue":"12","key":"709_CR64","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","volume":"27","author":"MH Williams","year":"2006","unstructured":"Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27(12):1485\u201394. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehi891\n                      \n                    .","journal-title":"Eur Heart J"},{"key":"709_CR65","unstructured":"Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster M et al. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017;35 Suppl 106(4):106\u201313."},{"issue":"2","key":"709_CR66","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/art.39432","volume":"68","author":"V Sobanski","year":"2016","unstructured":"Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J, et al. Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheumatol. 2016;68(2):484\u201393. \n                      https:\/\/doi.org\/10.1002\/art.39432\n                      \n                    .","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"709_CR67","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00408-017-0034-1","volume":"195","author":"A Gadre","year":"2017","unstructured":"Gadre A, Ghattas C, Han X, Wang X, Minai O, Highland KB. Six-minute walk test as a predictor of diagnosis, disease severity, and clinical outcomes in scleroderma-associated pulmonary hypertension: the DIBOSA study. Lung. 2017;195(5):529\u201336. \n                      https:\/\/doi.org\/10.1007\/s00408-017-0034-1\n                      \n                    .","journal-title":"Lung"},{"issue":"20","key":"709_CR68","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin L, Badesch DB. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148\u201357. \n                      https:\/\/doi.org\/10.1056\/NEJMoa050010\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"12","key":"709_CR69","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417\u201322.","journal-title":"J Rheumatol"},{"issue":"22","key":"709_CR70","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894\u2013903. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.839274\n                      \n                    .","journal-title":"Circulation"},{"issue":"2","key":"709_CR71","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","volume":"76","author":"M Humbert","year":"2017","unstructured":"Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis. 2017;76(2):422\u20136. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2015-209087\n                      \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"709_CR72","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","volume":"46","author":"N Galie","year":"2005","unstructured":"Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529\u201335. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2005.04.050\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"709_CR73","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1213917\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"12","key":"709_CR74","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"L Rubin","year":"2002","unstructured":"Rubin L, Badesch D, Barst RJ, Galie N, Black CM, Keogh AM, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903. \n                      https:\/\/doi.org\/10.1056\/NEJMoa012212\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"6","key":"709_CR75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425\u201334. \n                      https:\/\/doi.org\/10.7326\/0003-4819-132-6-200003210-00002\n                      \n                    .","journal-title":"Ann Intern Med"},{"issue":"5","key":"709_CR76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322\u20139. \n                      https:\/\/doi.org\/10.1056\/NEJMoa020204\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"11","key":"709_CR77","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","volume":"174","author":"VV McLaughlin","year":"2006","unstructured":"McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257\u201363. \n                      https:\/\/doi.org\/10.1164\/rccm.200603-358OC\n                      \n                    .","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"709_CR78","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800\u20134. \n                      https:\/\/doi.org\/10.1164\/rccm.2106079\n                      \n                    .","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"709_CR79","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","volume":"28","author":"RJ Barst","year":"2006","unstructured":"Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195\u2013203. \n                      https:\/\/doi.org\/10.1183\/09031936.06.00044406\n                      \n                    .","journal-title":"Eur Respir J"},{"issue":"2","key":"709_CR80","doi-asserted-by":"publisher","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","volume":"50","author":"S Gaine","year":"2017","unstructured":"Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galie N, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1602493. \n                      https:\/\/doi.org\/10.1183\/13993003.02493-2016\n                      \n                    .","journal-title":"Eur Respir J"},{"issue":"9","key":"709_CR81","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Galie","year":"2015","unstructured":"Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834\u201344. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1413687\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"7","key":"709_CR82","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","volume":"76","author":"JG Coghlan","year":"2017","unstructured":"\u2022\u2022 Coghlan JG, Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017;76(7):1219\u201327. \n                      https:\/\/doi.org\/10.1136\/annrheumdis-2016-210236\n                      \n                    . This subgroup analysis of 187 CTD-PAH patients (118 with SSc-PAH) showed that these patients experience a slower time to their first clinical failure event when treated with initial ambrisentan and tadalafil combination therapy compared to pooled monotherapy","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"709_CR83","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","volume":"192","author":"PM Hassoun","year":"2015","unstructured":"Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(9):1102\u201310. \n                      https:\/\/doi.org\/10.1164\/rccm.201507-1398OC\n                      \n                    .","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"709_CR84","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.39478","volume":"68","author":"MR Lammi","year":"2016","unstructured":"Lammi MR, Mathai SC, Saketkoo LA, Domsic RT, Bojanowski C, Furst DE, et al. Association between initial oral therapy and outcomes in systemic sclerosis-related pulmonary arterial hypertension. Arthritis Rheumatol. 2016;68(3):740\u20138. \n                      https:\/\/doi.org\/10.1002\/art.39478\n                      \n                    .","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"709_CR85","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1186\/ar4051","volume":"14","author":"GS Ngian","year":"2012","unstructured":"Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2012;14(5):R213. \n                      https:\/\/doi.org\/10.1186\/ar4051\n                      \n                    .","journal-title":"Arthritis Res Ther."},{"issue":"25","key":"709_CR86","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.115.018435","volume":"132","author":"IR Preston","year":"2015","unstructured":"Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation. 2015;132(25):2403\u201311. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018435\n                      \n                    .","journal-title":"Circulation"},{"issue":"1","key":"709_CR87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","volume":"129","author":"KM Olsson","year":"2014","unstructured":"Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014;129(1):57\u201365. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.004526\n                      \n                    .","journal-title":"Circulation"},{"issue":"12","key":"709_CR88","doi-asserted-by":"publisher","first-page":"e011028","DOI":"10.1136\/bmjopen-2016-011028","volume":"6","author":"A Calderone","year":"2016","unstructured":"Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, et al. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open. 2016;6(12):e011028. \n                      https:\/\/doi.org\/10.1136\/bmjopen-2016-011028\n                      \n                    .","journal-title":"BMJ Open"},{"issue":"3","key":"709_CR89","doi-asserted-by":"publisher","first-page":"R148","DOI":"10.1186\/ar3883","volume":"14","author":"E Grunig","year":"2012","unstructured":"Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther. 2012;14(3):R148. \n                      https:\/\/doi.org\/10.1186\/ar3883\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"709_CR90","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1513\/AnnalsATS.201503-177OC","volume":"13","author":"MM Crespo","year":"2016","unstructured":"Crespo MM, Bermudez CA, Dew MA, Johnson BA, George MP, Bhama J, et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann Am Thorac Soc. 2016;13(6):784\u201392. \n                      https:\/\/doi.org\/10.1513\/AnnalsATS.201503-177OC\n                      \n                    .","journal-title":"Ann Am Thorac Soc."},{"issue":"6","key":"709_CR91","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1513\/AnnalsATS.201512-806OC","volume":"13","author":"CH Miele","year":"2016","unstructured":"Miele CH, Schwab K, Saggar R, Duffy E, Elashoff D, Tseng CH, et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann Am Thorac Soc. 2016;13(6):793\u2013802. \n                      https:\/\/doi.org\/10.1513\/AnnalsATS.201512-806OC\n                      \n                    .","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"709_CR92","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.rmed.2013.09.015","volume":"107","author":"IY Khan","year":"2013","unstructured":"Khan IY, Singer LG, de Perrot M, Granton JT, Keshavjee S, Chau C, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med. 2013;107(12):2081\u20137. \n                      https:\/\/doi.org\/10.1016\/j.rmed.2013.09.015\n                      \n                    .","journal-title":"Respir Med"},{"issue":"5","key":"709_CR93","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/art.39021","volume":"67","author":"EJ Bernstein","year":"2015","unstructured":"Bernstein EJ, Peterson ER, Sell JL, D\u2019Ovidio F, Arcasoy SM, Bathon JM, et al. Survival of adults with systemic sclerosis following lung transplantation: a nationwide cohort study. Arthritis Rheumatol. 2015;67(5):1314\u201322. \n                      https:\/\/doi.org\/10.1002\/art.39021\n                      \n                    .","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0709-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0709-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T23:07:36Z","timestamp":1551308856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0709-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0709-5","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"27 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Chung reports grants from United Therapeutics, personal fees from Third Rock Venture, Reata, Gilead, and Actelion, outside the submitted work.Dr. Sundaram has no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Human and Animal Rights: All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"10"}}